ReviewActa pharmacologica Sinica2018
The circulating non-coding RNA landscape for biomarker research: lessons and prospects from cardiovascular diseases.
Review in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 104 citations in OpenAlex.
- Review
- Therapeutic modulation of HIV-1 using miRNAs and lncRNAs: from bench to bedside.Virology journal · 2026Review
- Silent controllers: non-coding RNAs drive autophagic response in myocardial ischemia reperfusion injury.Frontiers in cardiovascular medicine · 2026Review
- miRNA101a secreted by EATMs regulates atrial fibrillation through the PDGF-mediated PI3K/AKT pathway.Frontiers in pharmacology · 2026Article
- Peripheral blood RNA modifications as a novel diagnostic signature for polycystic ovary syndrome.Science China. Life sciences · 2025Article
- Circular RNAs in Cardiovascular Physiopathology: From Molecular Mechanisms to Therapeutic Opportunities.International journal of molecular sciences · 2025Review
- Blood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling.Nature communications · 2025Article
- Leveraging explainable multi-scale features for fine-grained circRNA-miRNA interaction prediction.BMC biology · 2025Article
- A Sensitive and Fast microRNA Detection Platform Based on CRlSPR-Cas12a Coupled with Hybridization Chain Reaction and Photonic Crystal Microarray.Biosensors · 2025Article
- Unlocking the therapeutic potential of tumor-derived EVs in ischemia-reperfusion: a breakthrough perspective from glioma and stroke.Journal of neuroinflammation · 2025Review
- The role of long non-coding RNAs and circular RNAs in immune evasion of influenza A virus: recent advances.Frontiers in cellular and infection microbiology · 2025Review
- Epigenetics of cardiomyopathies: the next frontier.Heart failure reviews · 2025Review
- Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction.Journal of lipid and atherosclerosis · 2024Review
- Research trends and hotspots of circular RNA in cardiovascular disease: A bibliometric analysis.Non-coding RNA research · 2024Article
- Review
- LOC102549726/miR-760-3p network is involved in the progression of ISO-induced pathological cardiomyocyte hypertrophy via endoplasmic reticulum stress.Journal of molecular histology · 2023Article
- Circular RNAs in atrial fibrillation: From bioinformatics analysis of circRNA-miRNA-mRNA network to serum expression.Biochemistry and biophysics reports · 2023Article
- An Uncharacterised lncRNA Coded by the ASAP1 Locus Is Downregulated in Serum of Type 2 Diabetes Mellitus Patients.International journal of molecular sciences · 2023Article
- [High expression of Circ-PALLD in heart failure is transcriptionally regulated by the transcription factor GATA4].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Angiogenesis after ischemic stroke.Acta pharmacologica Sinica · 2023Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pervasive transcription of the human genome is responsible for the production of a myriad of non-coding RNA molecules (ncRNAs) some of them with regulatory functions. The pivotal role of ncRNAs in cardiovascular biology has been unveiled in the last decade, starting from the characterization of the involvement of micro-RNAs in cardiovascular development and function, and followed by the use of circulating ncRNAs as biomarkers of cardiovascular diseases. The human non-coding secretome is composed by several RNA species that circulate in body fluids and could be used as biomarkers for diagnosis and outcome prediction. In cardiovascular diseases, secreted ncRNAs have been described as biomarkers of several conditions including myocardial infarction, cardiac failure, and atrial fibrillation. Among circulating ncRNAs, micro-RNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have been proposed as biomarkers in different cardiovascular diseases. In comparison with standard biomarkers, the biochemical nature of ncRNAs offers better stability and flexible storage conditions of the samples, and increased sensitivity and specificity. In this review we describe the current trends and future prospects of the use of the ncRNA secretome components as biomarkers of cardiovascular diseases, including the opening questions related with their secretion mechanisms and regulatory actions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.